A randomized, open-label, single-dose study to evaluate the safety and pharmacokinetics of two formulations containing 40 mg of fexuprazan in healthy Korean subjects
Int. Journal of Clinical Pharmacology and Therapeutics · 01.05.2026 · 64 (05) · 274-282
DOI: 10.5414/cp204926 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.05.2026. Verfasst von Joon Hur und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Gastrointestinal Agents.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Hur, J., Lee, J. A., Park, H., Choi, Y., Chae, J., Kwak, Y. G., Moon, S. J., & Kim, M. G. (2026). A randomized, open-label, single-dose study to evaluate the safety and pharmacokinetics of two formulations containing 40 mg of fexuprazan in healthy Korean subjects. Int. Journal of Clinical Pharmacology and Therapeutics, 64(05), 274-282. https://doi.org/10.5414/cp204926
Vancouver
Hur J, Lee JA, Park H, Choi Y, Chae J, Kwak YG, et al. A randomized, open-label, single-dose study to evaluate the safety and pharmacokinetics of two formulations containing 40 mg of fexuprazan in healthy Korean subjects. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(05):274-282. doi:10.5414/cp204926
BibTeX
@article{Hur2026,
author = {Hur, Joon and Lee, Jin A and Park, Hyung and Choi, Yongam and Chae, Jihye and Kwak, Yong-Geun and Moon, Seol Ju and Kim, Min-Gul},
title = {A randomized, open-label, single-dose study to evaluate the safety and pharmacokinetics of two formulations containing 40 mg of fexuprazan in healthy Korean subjects},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2026},
volume = {64},
number = {05},
pages = {274--282},
doi = {10.5414/cp204926}
}
EUVIMED